Justin Crowther

Justin Crowther
T: +44 (0) 115 957 8236
T: +44 (0) 20 7246 0500
E: justin.crowther@alantra.com

Justin is a Partner and has over 15 years of successful transaction advisory experience.

Justin is a Healthcare expert. Recent transactions include advising on the sale of 4Ways; the acquisition of Cornerstone Healthcare Group; advising Spectris plc on its £163m acquisition of Concept Life Sciences; the merger of Options Group with Outcomes First Group, the sales of Raphael HealthcareFocus Pharmaceuticals, the ARX Group, Williams Medical Supplies and Solor Care, and the management buy-outs of Addo Food Group and NRS.

He regularly writes for the sector's leading publications including HealthInvestor and Caring Times, and is often sought out by the national press, including the Financial Times, for his opinions. Justin is also one of the authors of the Alantra Pharma Fast 50.

Born and bred in Nottingham, Justin leads our presence with Simon Peacock in the East Midlands market, using his extensive connections with the region's corporate mid-market and intermediary professionals.

A graduate of Newcastle University, Justin trained as a chartered accountant with KPMG before moving onto the corporate development team of the then FTSE 100 company, Boots plc.

Justin combines his family duties with honing his tennis skills and taking as many opportunities as possible to play golf.

 

Alantra appoints experienced partner to head up its UK Real Estate & Hospitality team

Alantra has appointed Hoong Wey Woon as a Partner to head up its UK Real Estate & Hospitality team.  

Alantra advises Strong Roots on securing over €15.5m of investment

Alantra advises Strong Roots, one of the UK’s fastest-growing food companies, on securing over €15.5m of investment 

Alantra advises i2S on its sale to Gfi Informatique

Alantra advises Portuguese IT firm, i2S, on its sale to Gfi Informatique 

Alantra expands its technology sector team with two senior appointments

Alantra has expanded its Technology Media and Telecoms (TMT) sector team with two senior appointments. James Chapman-Andrews joins as Partner and Head of UK TMT and Simon Devonshire OBE, joins as Technology Industry Adviser.  

Alantra advises on sale of 3P Biopharmaceuticals to Keensight Capital

We advised Cinfa and the rest of the shareholders on the sale of 3P Biopharmaceuticals to Keensight Capital, a European growth private equity fund with deep expertise in healthcare.